Short Course Antibiotic Therapy

	Criteria for short duration*	Recommended duration
Enterobacteriaceae bacteremia	1. No ongoing focus of infection 2. For at least 48 hours: • Hemodynamically stable • Afebrile ➢ Urinary source most commonly evaluated ➢ Short duration not well studied in non-lactose fermenting GNRs (ex: *Pseudomonas aeruginosa*) ➢ Most common oral antibiotic – fluoroquinolone	7 days
Community-acquired pneumonia (CAP)	1. Afebrile for 48 hours 2. No more than 1 sign of clinical instability • SBP < 90mm Hg • HR > 100/min • RR > 24/min • Arterial O_2 <90% or PaO_2 <60 mmHg at room air	5 days
Hospital-acquired (HAP) & ventilator associated pneumonia (VAP)	No abscess or empyema	7 days
Aspiration	Pneumonia: Use CAP or HAP/VAP criteria depending on setting of acquisition	5-7 days
	Pneumonitis vs. pneumonia (if initiated in critically ill): re-evaluate antibiotic need based on clinical improvement & imaging/lab/micro studies	≤ 48 hours
COPD & chronic bronchitis exacerbation (suspected bacterial etiology)	None	0-5 days
Cystitis, no urologic abnormalities or systemic signs & symptoms	None	5 days – Nitrofurantoin 3 days – TMP/SMX, levofloxacin 1 day – Fosfomycin 1-3 days – Aminoglycoside 5 -7 days – Beta-lactam
Complicated cystitis & pyelonephritis	No urogenital abnormalities	7 days – IV beta-lactam 5 days – Levofloxacin 7-10 days - IV beta-lactam to PO switch
Catheter-associated UTI	1. Catheter removed 2. Prompt symptom resolution 3. No upper-UTI 4. Women < 65 years old	3-5 days
Intra-abdominal infection	Cholecystitis or appendicitis s/p source removal (no perforation). Gastroduodenal perf repaired within 24h & traumatic bowel perf repaired within 12h	24 hours post-surgery
	Cholecystitis or appendicitis s/p source removal (perforation). Complicated peritoneal infection w/ good source control	4 days
	Cholecystitis or complicated intra-abdominal infection w/ no source-control**	4-7 days
	Spontaneous bacterial peritonitis	5 days
	Ischemic colitis (moderate to severe disease)	7 days
Uncomplicated cellulitis (no abscess, ulcer, severe sepsis, bacteremia, chronic/recurrent cellulitis)	Patient likely to self-monitor & follow-up in primary care	5 days
Osteomyelitis s/p amputation w/ no residual infected bone or tissue	None	48 hours post-surgery

*In addition to clinical response to treatment

** Diagnostic investigation recommended for signs of infection beyond 5-7 days of antimicrobial therapy

References

1. Spellberg B. The New Antibiotic Mantra — "Shorter Is Better". JAMA Intern Med. 2016;176(9):1254–5.
2. Hanretty AM, Gallagher JC. Shortened course of antibiotics for bacterial infections: a systematic review of randomized controlled trials. Pharmacotherapy. 2018;38:674-687.
3. Yahav D, Franceschini E, Koppel F et al. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. *Clin Infect Dis* 2018; [Epub ahead of print].
4. Daneman N, Rishu AH, Ciong W, et al. Duration of antimicrobial treatment for bacteremia in Canadian critically ill patients. *Crit Care Med*. 2016; 44(2);256-64.
5. Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated gram-negative bloodstream infections. *Infection.* 2017;45(5):613-20.
6. Swamy S, Sharma RBS. Duration of treatment of gram-negative bacteremia: are shorter courses of antimicrobial therapy feasible? *Infec Dis Clin Prac*. 2016;24(3):155-60.
7. Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. *Clin Infect Dis*. 2018;66(2):172-177.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44 Suppl: S27–72.
9. Uranga A, Espana PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. *JAMA* 2016;176(9):1257-65.
10. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with health-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61–e111.
11. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs. long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. *Chest*. 2013;144:1759–1767.
12. Pugh R, Grant C, Cooke RP, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. *Cochrane Database Syst Rev*. 2015 Aug 24;(8):CD007577.
13. Mandell LA, Niederman MS. Aspiration Pneumonia. *N Engl J Med* 2019;380:651-63
14. Dragan V, Wei Y, Elligsen M, et al. Prophylactic antimicrobial therapy for acute aspiration pneumonitis. *Clin Infect Dis* 2018;67(4):513-8.
15. El-Moussaoui, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. *Thorax*. 2008;63:415-422.
16. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. *J Antimicrob Chemother*. 2008;62:442-450.
17. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011;52(5):e103–20.
18. Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy? *Antimicrob Agents Chemother* 2018;63(1):e02165-18.
19. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. *Urology* 2008;71(1): 17–22.
20. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. *Lancet* 2012;380(9840):484–90.
21. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet* 2015;385(9981):1949-56.
22. Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for injection vs piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS a phase 2/3 randomized trial. *Clin Infect Dis* 2019; [Epub ahead of print].
23. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection – 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013;68(10):2183-91.
24. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Disease Society of America. *Clin Infect Dis* 2010;50(5):625-63.
25. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:133-164.
26. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. *Surg Infect* (Larchmt) 2017;18:1-76.
27. Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci* 2018;25:3-16.
28. Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. *World J Emerg Surg* 2017;12:29.
29. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015;372:1996-2005.
30. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991;100(6):1737.
31. Brandt LJ, Feuerstadt P, Longstreth GF. ACG Clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia. Am J Gastroenterol 2015;111:18-44.
32. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59(2):e10-e52.
33. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. *Arch Intern Med* 2004;164(15):1669–74.
34. Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* 2014;14(8):696–705.
35. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis* 2012;54(12):e132-e173.
36. Rossel A, Lebowitz D, Gariani K, et al. Stopping antibiotics after surgical amputation in diabetic foot and ankle infections – a daily practice cohort. *Endocrinol Diabetes Metab* 2019;2(2):1-7.

© Copyright 2025 CommonSpirit Health. All rights reserved.
Shared only for your personal use in the context of you or your organization providing medical services on behalf of or in coordination with CommonSpirit.